Shanxi C&Y Pharmaceutical Initiates Clinical Study for Generic Ferric Maltol with NMPA Approval
CompanyDrug

Shanxi C&Y Pharmaceutical Initiates Clinical Study for Generic Ferric Maltol with NMPA Approval

Boji Medical Technology Receives NMPA Approval for TBA Clinical Study in Drug-Resistant Tuberculosis
CompanyDrug

Boji Medical Technology Receives NMPA Approval for TBA Clinical Study in Drug-Resistant Tuberculosis

Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for Prostate Cancer and Solid Tumor Clinical Trials
CompanyDrug

Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for Prostate Cancer and Solid Tumor Clinical Trials

Sichuan Biokin's BL-M08D1 and CSPC's SYS6010 Eye Breakthrough Therapy Designations in China
CompanyDrug

Sichuan Biokin’s BL-M08D1 and CSPC’s SYS6010 Eye Breakthrough Therapy Designations in China

CDE Indicates Priority Review for Boehringer Ingelheim's Zongertinib and Peers
CompanyDrug

CDE Indicates Priority Review for Boehringer Ingelheim’s Zongertinib and Peers

Zelgen Biopharmaceuticals' ZG005 Gets NMPA Green Light for Solid Tumor and Lymphoma Clinical Trial
CompanyDrug

Zelgen Biopharmaceuticals’ ZG005 Gets NMPA Green Light for Solid Tumor and Lymphoma Clinical Trial

Western Chongqing Southern Sichuan Precision Medicine Center Digital Platform Launches in Rongchang District
Company

Western Chongqing Southern Sichuan Precision Medicine Center Digital Platform Launches in Rongchang District

ProteLight Pharma's Peceleganan (PL-5) Accepted for Review by China's CDE
CompanyDrug

ProteLight Pharma’s Peceleganan (PL-5) Accepted for Review by China’s CDE

Innovent Biologics Partners with Suzhou ForLong to Explore Sintilimab and FL115 Combination in Solid Tumors
CompanyDeals

Innovent Biologics Partners with Suzhou ForLong to Explore Sintilimab and FL115 Combination in Solid Tumors

Zhejiang Huahai Pharmaceutical's Subsidiary Huaota Bio Secures $27.4 Million Investment
CompanyDeals

Zhejiang Huahai Pharmaceutical’s Subsidiary Huaota Bio Secures $27.4 Million Investment

Bristol-Myers Squibb's Sotyktu Meets Primary Endpoints in POETYK PsA Studies
CompanyDrug

Bristol-Myers Squibb’s Sotyktu Meets Primary Endpoints in POETYK PsA Studies

Bio-Thera Solutions Enters Licensing Agreement with Tabuk Pharmaceutical for BAT2206 in Saudi Arabia
CompanyDeals

Bio-Thera Solutions Enters Licensing Agreement with Tabuk Pharmaceutical for BAT2206 in Saudi Arabia